

ESPGHAN Monothematic Conference: Management of Progressive Liver Diseases

General Information

Programme

Faculty

Application Deadline: 07.01.2018

Registration Fee

Trainee Member Regular Fee (200.00€)

Member Regular Fee (350.00€)

Non-Member Regular fee (450.00€)



ESPGHAN
European Society for Paediatric
Gastroenterology, Hepatology and Nutrition

**ESPGHAN
MONOTHEMATIC
CONFERENCE:
MANAGEMENT OF PROGRESSIVE
LIVER DISEASES**

**FEBRUARY 01-03, 2018
BRUSSELS, BELGIUM**

www.espghan.org

Programme MTC Brussels February 1st-3rd 2018

Thursday Feb 01

Lunch: 1200 to 1300

Welcome and Introduction : 1300 to 1315

Pathogenesis of Fibrosis

Pathogenetic mechanisms in liver fibrosis (M. Pinzani)

Liver and Gut axis- it takes two to tango (Ye Htun Oo)

Gut microbiota in liver disease- friend or foe (Amandine Everard)

Assessment of liver fibrosis

Biomarkers for liver fibrosis (E. Fitzpatrick)

Non-invasive tests for liver fibrosis (U. Baumann)

Liver biopsy- pitfalls in assessment of fibrosis (R. Brown)

Key note lecture

Liver scarring- prevention is better than cure (J. Fallowfield)

Friday Feb 02

Current concepts in management and focus on recent advances

Reversible liver disease

Abstracts

NAFLD and NASH –are both reversible (P. Socha)

Autoimmune liver disease-when is it too late for medical Rx (D. Hadzic)

Intestinal failure associated liver disease- changing pattern (F. Lacaille)

Progressive liver disease

Abstracts

Primary sclerosing cholangitis - future treatment strategies (G. Hirschfeld)

PFIC- is it possible to prevent disease progression? (H. Verkade)

Biliary Atresia - Reversing Disease (L. Hierro)

Lunch

Complications of progressive liver disease

Abstracts

Portal hypertension- medical treatments (F. Smets)

Hepatopulmonary syndrome and PPS- forgotten entities (D. Debray)

Minimal Hepatic encephalopathy - what's new (V. McLin)

Keynote lecture

Acute on chronic liver failure (TBC)

Summary of the day

Conference dinner for all participants

Saturday Feb 3

Newer therapies in progressive liver disease

Abstracts

Drug targeting strategies in progressive liver disease (Ruchi Bansal)

Gene therapy for liver based monogenic disease (L. D'Antiga)

Liver derived mesenchymal cells for fibro-inflammatory liver diseases (E. Sokal)

Current research possibilities into progressive liver disease

European Reference Network "Rare Liver" (E. Sturm)

Research strategies and summary

Contact